Addressing the blind spot of cancer care innovation: health inequity
- 5 April 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (6), 668-670
- https://doi.org/10.1016/j.annonc.2020.03.298
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- A reality check of the accelerated approval of immune-checkpoint inhibitorsNature Reviews Clinical Oncology, 2019
- Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019JAMA, 2019
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2018
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Accelerated Approval and Expensive Drugs — A Challenging CombinationThe New England Journal of Medicine, 2017
- Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and NeckFrontiers in Oncology, 2016
- Structural competency: Theorizing a new medical engagement with stigma and inequalitySocial Science & Medicine (1982), 2014
- How Quickly Do Physicians Adopt New Drugs? The Case of Second-Generation AntipsychoticsPsychiatric Services, 2013
- National Estimates of Out-of-Pocket Health Care Expenditure Burdens Among Nonelderly Adults With Cancer: 2001 to 2008Journal of Clinical Oncology, 2011
- Quantifying Income-Related Inequality in Healthcare Delivery in the United StatesMedical Care, 2004